Category Archives: Life Sciences

A global discussion on health care policy and innovation

Health care systems across the globe are as dynamic and complex as the populations they serve. Yet as varied as they are, they encounter common challenges as they strive toward the same goal — establishing and maintaining effective, affordable health care for their constituents. Last month, global experts and stakeholders convened to address some of […]
Read More »

Using GIS to track Zika and microcephaly

For almost a year, the United States watched from afar as the number of Zika cases in Central and South America grew, with increasing numbers of infants born with the debilitating brain malformation known as microcephaly. As of August 31st, 2016, just over 2,700 cases of Zika had been reported in the U.S. — 35 […]
Read More »

ISPOR Asia-Pacific: Working Toward a Healthier Population in APAC

The past decade has been incredibly busy and productive for health economics outcomes research (HEOR) and health technology assessment (HTA) in the Asia-Pacific (APAC) region. In an effort to ensure equitable and affordable access to quality health care solutions while making costs sustainable, many APAC countries have developed and implemented evidence-based HTA guidelines and policies […]
Read More »

Epidemiologic principles: Uncovering actionable insights and real-world evidence

You may be surprised to learn how often you employ epidemiologic principles in your everyday life. The simple act of making a choice may involve applications of epidemiologic methods. For example, when comparing two breakfast cereals or deciding between two mutual funds to invest in, you might use a systematic approach to evaluate the pros […]
Read More »

ISPOR Europe: Closing the gap between research and actionable outputs

Last month, thousands of global researchers, thought leaders and life sciences industry peers gathered in Italy for the 18th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). We were all there in the name of health economics and outcomes research, which is very appropriate given that health economics was first […]
Read More »

Adapting epidemiologic principles to “big data”

Optum’s epidemiology experts apply the rigor of advanced epidemiologic methods to the challenges inherent in “big data” The term “big data” is ubiquitous these days. Within healthcare, electronic data from administrative systems and electronic health records (EHRs) are increasingly voluminous, varied and accessible. Within health care and public health, our capacity to use data has […]
Read More »

A look back at the ISPOR Annual International Meeting

Last week, participants from across our enterprise gathered in Philadelphia to contribute to the 20th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) conference. ISPOR advances the policy, science, and practice of pharmacoeconomics (or health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being, including […]
Read More »

The Power of Real-World Evidence

Next week, May 16 – 20, Optum colleagues, clients, industry peers, global researchers and thought leaders are gathering in Philadelphia at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting. I’m looking forward to convening with our clients, discussing our progress and brainstorming about the new challenges to be tackled. Reflecting […]
Read More »

ISPOR Europe; A distinctive opportunity at the forefront of great change

In approximately 2 weeks, 3,800 global researchers and thought leaders will be coming together in Amsterdam to explore “New Challenges for Improving European Health Care” at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress, November 8-12. The conference is a great opportunity for us to interface with clients, partners and […]
Read More »

ISPOR, Optum and the Power of Real-World Data

The life sciences industry is facing unprecedented opportunities and challenges, and I’m excited. We’re entering new and diverse markets, unlike any we’ve experienced before, while at the same time the dynamics in existing markets are becoming more complex due to health care transformation efforts.